Product Sales (Tables)

6 Months Ended

Jun. 30, 2018

Net product sales consist of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
Net Product Sales in the United States	2018		2017		2018		2017
EYLEA^®	$	991,998	$	919,466	$	1,976,047	$	1,773,853
ARCALYST^®	4,384		4,667		8,244		8,525
	$	996,382	$	924,133	$	1,984,291	$	1,782,378

The collaboration revenue we earned from Sanofi is detailed below:



	Three Months Ended June 30,						Six Months Ended June 30,
Sanofi Collaboration Revenue	2018			2017			2018			2017
Antibody:
Reimbursement of Regeneron research and development expenses	$	64,482		$	137,272		$	124,876		$	292,517
Reimbursement of Regeneron commercialization-related expenses	103,666			87,104			189,090			160,663
Regeneron's share of losses in connection with commercialization of antibodies	(68,797		)	(122,281		)	(143,671		)	(230,683		)
Other	31,654			31,204			48,984			42,490
Total Antibody	131,005			133,299			219,279			264,987
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	77,054			68,080			150,878			126,759
Reimbursement of Regeneron commercialization-related expenses	2,061			749			3,271			749
Other	27,633			20,000			53,815			40,000
Total Immuno-oncology	106,748			88,829			207,964			167,508
	$	237,753		$	222,128		$	427,243		$	432,495

Revenue earned in connection with our Bayer EYLEA collaboration is detailed below:



	Three Months Ended June 30,				Six Months Ended June 30,
Bayer EYLEA Collaboration Revenue	2018		2017		2018		2017
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	246,302	$	190,883	$	478,370	$	365,759
Reimbursement of Regeneron EYLEA development expenses	3,678		2,329		7,135		4,780
Other	12,694		10,593		24,557		21,196
	$	262,674	$	203,805	$	510,062	$	391,735

Schedules of Concentration of Risk, by Risk Factor

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the three and six months ended June 30, 2018 and 2017. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Besse Medical, a subsidiary of AmerisourceBergen Corporation	56	%	50	%	55	%	51	%
McKesson Corporation	35	%	29	%	37	%	28	%
Curascript SD Specialty Distribution, a subsidiary of Express Scripts	**		20	%	**		20	%
** Sales to Curascript SD Specialty Distribution represented less than 10% of total gross product revenue during the period.

Sales Related Deductions Activity

The following table summarizes the provisions, and credits/payments, for these sales-related deductions during the six months ended June 30, 2018 and 2017.



	Rebates, Chargebacks, and Discounts			Distribution- Related Fees			Other Sales- Related Deductions			Total
Balance as of December 31, 2017	$	29,840		$	34,142		$	21,320		$	85,302
Provisions	97,698			102,133			19,892			219,723
Credits/payments	(91,108		)	(98,532		)	(24,431		)	(214,071		)
Balance as of June 30, 2018	$	36,430		$	37,743		$	16,781		$	90,954

Balance as of December 31, 2016	$	12,712		$	29,465		$	3,674		$	45,851
Provisions	78,250			90,077			20,531			188,858
Credits/payments	(67,850		)	(90,519		)	(21,312		)	(179,681		)
Balance as of June 30, 2017	$	23,112		$	29,023		$	2,893		$	55,028